Fidarestat improves cardiomyocyte contractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism

Journal of Hypertension

Volumn 25, Issue 10, 2007, Pages 2138-2147

  Dong, Feng ^a   Ren, Jun ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

Cardiac contraction; Diabetes; Fidarestat; Histone deacetylase Sir2

Indexed keywords

CALCIUM ION; ENZYME INHIBITOR; FIDARESTAT; HISTONE DEACETYLASE; I KAPPA B; SILENT INFORMATION REGULATOR PROTEIN 2; SPLITOMICIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CONTROLLED STUDY; DEACETYLATION; DIABETIC OBESITY; DOSE RESPONSE; DRUG EFFECT; ENZYME PHOSPHORYLATION; HEART CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; MALE; MOUSE; MOUSE STRAIN; MUSCLE LENGTH; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 34748858009     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32828626d1     Document Type: Article

References (35)

1. Ren J, Ceylan-Isik AF. Diabetic cardiomyopathy: do women differ from men? Endocrine 2004; 25:73-83.
2. Ren J, Sowers JR, Walsh MF, Brown RA. Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol 2000; 279:H1708-H1714.
3. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 2002; 105:2923-2928.
4. Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol 2004; 181:1-10.
5. Dong F, Zhang X, Yang X, Esberg LB, Yang H, Zhang Z, et al. Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice. J Endocrinol 2006; 188:25-36.
6. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 2006; 47:222-229.
7. Minhas KM, Khan SA, Raju SV, Phan AC, Gonzalez DR, Skaf MW, et al. Leptin repletion restores depressed β-adrenergic contractility in ob/ob mice independently of cardiac hypertrophy. J Physiol 2005; 565:463-474.
8. Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004; 53:3201-3208.
9. Amano S, Yamagishi S, Kato N, Inagaki Y, Okamoto T, Makino M, et al. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem Biophys Res Commun 2002; 299:183-188.
10. Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, Srivastava D, et al. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 2006; 114:1838-1846.
11. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50:21-33.
12. Gray SG, De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev 2005; 21:416-433.
13. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403:795-800.
14. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000; 14:1021-1026.
15. Crow MT. Sir-viving cardiac stress: cardioprotection mediated by a longevity gene. Circ Res 2004; 95:953-956.
16. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004; 95:971-980.
17. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 2000; 36:501-505.
18. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 2004; 18:1192-1199.
19. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997; 46:292-300.
20. Wold LE, Ceylan-Isik AF, Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 2005; 26:908-917.
21. Kiyono Y, Kajiyama S, Fujiwara H, Kanegawa N, Saji H. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG. Eur J Nucl Med Mol Imaging 2005; 32:993-997.
22. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003; 52:864-871.
23. Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens MJ, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54:234-242.
24. Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 2004; 27:448-454.
25. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10:2247-2258.
26. Ahn KS, Aggarwal BB. Transcription factor NF-κB: a sensor for smoke and stress signals. Ann NY Acad Sci 2005; 1056:218-233.
27. Siddiqui MR, Moorthy K, Taha A, Hussain ME, Baquer NZ. Low doses of vanadate and Trigonella synergistically regulate Na(+)/K(+)-ATPase activity and GLUT4 translocation in alloxan-diabetic rats. Mol Cell Biochem 2006; 285:17-27.
28. Ramasamy R, Liu H, Oates PJ, Schaefer S. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat. Cardiovasc Res 1999; 42:130-139.
29. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995; 25:1111-1115.
30. Davidoff AJ, Davidson MB, Carmody MW, Davis ME, Ren J. Diabetic cardiomyocyte dysfunction and myocyte insulin resistance: role of glucose-induced PKC activity. Mol Cell Biochem 2004; 262:155-163.
31. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled doubleblind parallel group study. Diabetes Care 2001; 24:1776-1782.
32. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13:2570-2580.
33. Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Meneur C, et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005; 2:105-117.
34. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434:113-118.
35. Sakamoto J, Miura T, Shimamoto K, Horio Y. Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett 2004; 556:281-286.